Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th
Oct 03, 2023
The presentation will provide clinical development and business updates including Windtree’s progress on its lead product candidate istaroxime in cardiogenic shock.
Click here to register and attend the event: Click here
Istaroxime is a first-in-class dual mechanism therapy designed to improve both systolic and diastolic cardiac function. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm. Data from multiple Phase 2 studies in patients with early cardiogenic shock or acute decompensated heart failure demonstrate that istaroxime infused intravenously significantly improves cardiac function and blood pressure without increasing heart rate or the incidence of cardiac rhythm disturbances.
Source: Windtree Therapeutics